经皮耳穴迷走神经刺激预防肩关节镜术后肌间沟阻滞反跳痛
这项单中心随机假对照试验纳入120例接受超声引导单次肌间沟臂丛阻滞的肩关节镜手术成人患者,比较围术期经皮耳穴迷走神经刺激(taVNS)与假刺激。taVNS组术后24小时内反跳痛发生率为20.0%,假刺激组为43.3%,绝对风险降低23.3%(95%CI 7.2%至39.5%),且taVNS组静息和运动诱发疼痛评分更低、恢复质量与睡眠质量更优,无刺激相关不良事件。
要点
- 围术期taVNS可降低单次肌间沟阻滞后24小时内反跳痛发生率(20.0% vs 43.3%)。
- taVNS组静息和运动诱发疼痛评分轻度降低,恢复质量和睡眠质量改善。
- 两组累计舒芬太尼消耗量差异无统计学意义(P=0.056),未观察到刺激相关不良事件。
核心结论
- 围术期taVNS可能降低肩关节镜手术患者单次肌间沟阻滞后的反跳痛发生率。
- taVNS与疼痛评分轻度降低、恢复质量和睡眠质量改善相关,且不增加不良事件。
研究设计与样本
- 单中心、随机、参与者与评估者盲法、假对照试验,纳入120例择期肩关节镜手术并接受超声引导单次肌间沟臂丛阻滞的成人患者,按1:1随机接受活性taVNS或假刺激。
- 活性刺激于围术期应用,并持续至术后第1天和第2天;主要结局为术后24小时内反跳痛发生率。
主要发现
- 反跳痛在taVNS组60例中发生12例(20.0%),假刺激组60例中发生26例(43.3%);绝对风险降低23.3%(95%CI 7.2%至39.5%),需治疗人数4.3(95%CI 2.5至13.9),相对风险0.46(95%CI 0.26至0.82),P=0.006。
- taVNS组静息疼痛评分平均差异-0.50(95%CI -0.63至-0.37,P<0.001),运动诱发疼痛评分平均差异-0.39(95%CI -0.65至-0.14,P=0.003)。
- taVNS组术后第1天和第2天QoR-15评分更高,手术当晚和术后第1晚睡眠质量更好(均P<0.01)。
- 两组累计舒芬太尼消耗量差异无统计学意义(几何均数比0.67,95%CI 0.44至1.01,P=0.056)。
- 未观察到刺激相关不良事件。
临床怎么用
- 对于接受单次肌间沟臂丛阻滞的肩关节镜手术患者,可考虑围术期应用taVNS以降低反跳痛风险。
- taVNS可作为区域麻醉后反跳痛管理的辅助非药物手段,且不增加不良事件。
局限性
- 单中心研究,样本量120例,结论外推需谨慎。
- 累计舒芬太尼消耗量差异未达统计学显著性(P=0.056)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rebound pain frequently occurs after resolution of single-shot interscalene brachial plexus block (ISB) and may diminish the overall analgesic benefit of regional anesthesia. Transcutaneous auricular vagus nerve stimulation (taVNS) has demonstrated analgesic and anti-inflammatory properties, but its effect on rebound pain after shoulder arthroscopy remains unclear. METHODS: In this single-center, randomized, participant- and assessor-blinded, sham-controlled trial, 120 adults undergoing elective arthroscopic shoulder surgery with ultrasound-guided single-shot ISB were randomized 1:1 to receive either active taVNS or sham stimulation. Active stimulation was applied perioperatively and continued on postoperative days 1 and 2. The primary outcome was the incidence of rebound pain within 24 hours after surgery. Secondary outcomes included postoperative pain scores, cumulative sufentanil consumption, quality of recovery (QoR-15), sleep quality (Richards-Campbell Sleep Questionnaire), and adverse events. RESULTS: One hundred twenty participants completed the study and were included in the intention-to-treat analysis. Rebound pain occurred in 12 of 60 patients (20.0%) assigned to taVNS compared with 26 of 60 patients (43.3%) assigned to sham stimulation (absolute risk reduction 23.3%, 95% CI 7.2% to 39.5%; number needed to treat 4.3, 95% CI 2.5 to 13.9; relative risk 0.46, 95% CI 0.26 to 0.82; p=0.006). taVNS was associated with lower resting pain scores (mean difference -0.50, 95% CI -0.63 to -0.37; p<0.001) and movement-evoked pain scores (mean difference -0.39, 95% CI -0.65 to -0.14; p=0.003). Patients receiving taVNS demonstrated higher QoR-15 scores on postoperative days 1 and 2 and better sleep quality on the night of surgery and postoperative night 1 (all p<0.01). The between-group difference in cumulative sufentanil consumption was not statistically significant (GMR 0.67, 95% CI 0.44 to 1.01; p=0.056). No stimulation-related adverse events were observed. CONCLUSIONS: Perioperative taVNS may reduce the incidence of rebound pain following single-shot ISB in patients undergoing arthroscopic shoulder surgery. taVNS was also associated with modest reductions in pain scores and improvements in quality of recovery and sleep quality without an increase in adverse events. TRIAL REGISTRATION NUMBER: ChiCTR2500107694.
引用
- Zhang J, Lu S, Lin S, et al. Transcutaneous auricular vagus nerve stimulation to prevent rebound pain after interscalene block for arthroscopic shoulder surgery. Reg Anesth Pain Med. 2026. PMID: 42744405. doi:10.1136/rapm-2026-108256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。